Close more info panel ClinicalThought ClinicalThought My Perspective on the Use of PARP Inhibition in Pancreatic Cancer Treatment View ClinicalThought View More
Now that olaparib is approved in the EU, how will your treatment of patients with pancreatic cancer change? Dirk Arnold, MD, PhD Released: October 30, 2020